Kallionpaa R, Maattanen J, Leppavirta J, Peltonen S, Peltonen J
Genes Chromosomes Cancer. 2025; 64(2):e70017.
PMID: 39985314
PMC: 11846020.
DOI: 10.1002/gcc.70017.
Ahmadi V, Karimi N, Evans A, Karaduman A
Indian J Dermatol. 2025; 70(1):11-17.
PMID: 39896307
PMC: 11784969.
DOI: 10.4103/ijd.ijd_141_24.
Oteiza-Rius I, Estenaga Perez de Albeniz A, Hernandez-Martin A, Alfageme Roldan F, Garcia-Martinez F
J Ultrasound Med. 2024; 44(4):703-709.
PMID: 39665148
PMC: 11892087.
DOI: 10.1002/jum.16632.
Bashiri F, Hundallah K, Abukhaled M, Alyahya M, Al Futaisi A, Alshowaeir D
Front Oncol. 2024; 14:1323176.
PMID: 39257551
PMC: 11385870.
DOI: 10.3389/fonc.2024.1323176.
Ota M, Nobeyama Y, Asahina A
JMA J. 2024; 7(2):205-212.
PMID: 38721077
PMC: 11074565.
DOI: 10.31662/jmaj.2023-0161.
Global research trends in cutaneous neurofibromas: A bibliometric analysis from 2003 to 2022.
Wang J, Fu J, Zhou Y, Gao D, Qing J, Yang G
Skin Res Technol. 2024; 30(2):e13595.
PMID: 38279591
PMC: 10818123.
DOI: 10.1111/srt.13595.
Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.
Mazuelas H, Magallon-Lorenz M, Uriarte-Arrazola I, Negro A, Rosas I, Blanco I
JCI Insight. 2024; 9(3).
PMID: 38175707
PMC: 11143965.
DOI: 10.1172/jci.insight.168826.
Treatment of Cutaneous Neurofibromas in Patients with Neurofibromatosis Type 1.
Wozniak B, Bove T, Zawada T, Calik J
Case Rep Dermatol. 2023; 15(1):194-201.
PMID: 37899948
PMC: 10601743.
DOI: 10.1159/000534270.
Superimposed Mosaicism in the Form of Extremely Extended Segmental Plexiform Neurofibroma Caused by a Novel Pathogenic Variant in the NF1 Gene.
Veres K, Bene J, Hadzsiev K, Garami M, Palla S, Happle R
Int J Mol Sci. 2023; 24(15).
PMID: 37569527
PMC: 10418935.
DOI: 10.3390/ijms241512154.
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Cannon A, Sarin K, Petersen A, Pichard D, Wolters P, Erickson G
Clin Trials. 2023; 21(1):67-72.
PMID: 37269078
PMC: 10735167.
DOI: 10.1177/17407745231178839.
ERN GENTURIS tumour surveillance guidelines for individuals with neurofibromatosis type 1.
Carton C, Evans D, Blanco I, Friedrich R, Ferner R, Farschtschi S
EClinicalMedicine. 2023; 56:101818.
PMID: 36684394
PMC: 9845795.
DOI: 10.1016/j.eclinm.2022.101818.
Characterization of health concerns in people with neurofibromatosis type 1.
Fleming J, Morgan O, Wong C, Schlub T, Berman Y
Mol Genet Genomic Med. 2022; 11(1):e2077.
PMID: 36444392
PMC: 9834143.
DOI: 10.1002/mgg3.2077.
[Treatment and progress of cutaneous neurofibroma].
Zhu B, Wei C, Wang W, Gu B, Li Q, Wang Z
Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2022; 36(9):1064-1071.
PMID: 36111466
PMC: 9626300.
DOI: 10.7507/1002-1892.202205072.
Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
Maguiness S, Berman Y, Rubin N, Dodds M, Plotkin S, Wong C
Neurology. 2021; 97(7 Suppl 1):S25-S31.
PMID: 34230204
PMC: 8594000.
DOI: 10.1212/WNL.0000000000012427.
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
Cannon A, Pichard D, Wolters P, Adsit S, Erickson G, Lessing A
Neurology. 2021; 97(7 Suppl 1):S15-S24.
PMID: 34230202
PMC: 8594006.
DOI: 10.1212/WNL.0000000000012425.
Status and Recommendations for Incorporating Biomarkers for Cutaneous Neurofibromas Into Clinical Research.
Wallis D, Stemmer-Rachamimov A, Adsit S, Korf B, Pichard D, Blakeley J
Neurology. 2021; 97(7 Suppl 1):S42-S49.
PMID: 34230199
PMC: 8594001.
DOI: 10.1212/WNL.0000000000012426.
Piebaldism Associated with Café-au-lait Macules and Intertriginous Freckling: A Case Report and Review of the Literature.
Akarsu S, Ilknur T, Avci C, Fetil E
Ann Dermatol. 2021; 31(5):567-570.
PMID: 33911651
PMC: 7992560.
DOI: 10.5021/ad.2019.31.5.567.
Photodynamic Therapy for Benign Cutaneous Neurofibromas Using Aminolevulinic Acid Topical Application and 633 nm Red Light Illumination.
Quirk B, Olasz E, Kumar S, Basel D, Whelan H
Photobiomodul Photomed Laser Surg. 2021; 39(6):411-417.
PMID: 33470897
PMC: 8219184.
DOI: 10.1089/photob.2020.4957.
Clinical picture and treatment of cutaneous lesions in patients with neurofibromatosis type 1.
Fijalkowska M, Antoszewski B
Postepy Dermatol Alergol. 2020; 37(5):781-784.
PMID: 33240020
PMC: 7675077.
DOI: 10.5114/ada.2020.100488.
Genome-wide association study of café-au-lait macule number in neurofibromatosis type 1.
Sung H, Hyland P, Pemov A, Sabourin J, Baldwin A, Bass S
Mol Genet Genomic Med. 2020; 8(10):e1400.
PMID: 32869517
PMC: 7549607.
DOI: 10.1002/mgg3.1400.